A second open letter to NIH for revisions to CCP recommendations
11 Comments
M
Melissa Edwards
Featured
Please help give immunocompromised individuals all the options we can get to fight COVID.
R
Rita A Reik MD FCAP
Featured
It is critical that clinicians remain aware of very high-titer COVID-19 convalescent plasma as an FDA-authorized therapy. It offers an advantage over pharmaceuticals in that it is produced real time and reflects the most recent variants circulating in the population.
D
Daniel F Hanley
Featured
Legum Professor Acute Care Neurology,
Director Multisite Clinical Trials Johns Hopkins ICTR
B
Barry Meisenberg MD
We will likely need this tool
B
Brian Koffman MDCM MS Ed
Featured
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.
M
Mei Chang
Featured
Please help increase access to important therapeutic options, particularly for our immunocompromised population.
M
MarieElena Cordisco MA NPC APRN
This is an important and lifesaving therapy
J
Johanna Patricia Daily
CCP would provide us an option for our patients who are immunocompromised.
J
Josh Nosanchuk
This is a life-saving therapy!
W
Walter Ian Lipkin
Featured
John Snow Professor of Epidemiology
Mailman School of Public Health
Columbia University
Please help give immunocompromised individuals all the options we can get to fight COVID.
It is critical that clinicians remain aware of very high-titer COVID-19 convalescent plasma as an FDA-authorized therapy. It offers an advantage over pharmaceuticals in that it is produced real time and reflects the most recent variants circulating in the population.
Legum Professor Acute Care Neurology, Director Multisite Clinical Trials Johns Hopkins ICTR
We will likely need this tool
Brian Koffman MDCM (retired) MS Ed Co-Founder, Executive VP and Chief Medical Officer CLL Society, Inc.
Please help increase access to important therapeutic options, particularly for our immunocompromised population.
This is an important and lifesaving therapy
CCP would provide us an option for our patients who are immunocompromised.
This is a life-saving therapy!
John Snow Professor of Epidemiology Mailman School of Public Health Columbia University
Thx.